MCID: GLL048
MIFTS: 51

Glial Tumor

Categories: Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glial Tumor

MalaCards integrated aliases for Glial Tumor:

Name: Glial Tumor 58
Glioma 58

Characteristics:

Orphanet epidemiological data:

58
glial tumor
Prevalence: 1-9/100000 (United States),1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

MESH via Orphanet 45 D005910
UMLS via Orphanet 71 C0017638
Orphanet 58 ORPHA182067

Summaries for Glial Tumor

MalaCards based summary : Glial Tumor, also known as glioma, is related to diffuse midline glioma, h3 k27m-mutant and gliosarcoma. An important gene associated with Glial Tumor is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Glioma and MicroRNAs in cancer. The drugs Midazolam and Phenytoin have been mentioned in the context of this disorder. Affiliated tissues include brain, endothelial and t cells, and related phenotypes are Increased Akt phosphorylation after EGF stimulation and cellular

Wikipedia : 73 Glial tumor is a general term for numerous tumors of the central nervous system, including astrocytomas,... more...

Related Diseases for Glial Tumor

Diseases related to Glial Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1060)
# Related Disease Score Top Affiliating Genes
1 diffuse midline glioma, h3 k27m-mutant 32.2 OLIG2 BRCA2
2 gliosarcoma 31.4 PTEN OLIG2 EGFR
3 diffuse astrocytoma 30.8 OLIG2 EGFR
4 gliomatosis cerebri 30.5 PTEN EGFR
5 malignant astrocytoma 30.3 PTEN OLIG2 EGFR
6 neurofibromatosis, type i 30.3 PTEN EGFR BRCA2
7 neurofibroma 30.2 PTEN EGFR
8 central nervous system cancer 30.1 PTEN OLIG2 EGFR
9 li-fraumeni syndrome 30.0 PTEN EGFR BRCA2
10 adenocarcinoma 29.8 PTEN EGFR BRCA2
11 glioma 29.8 TNC PTEN EGFR BRCA2
12 mixed glioma 29.7 PTEN OLIG2 EGFR
13 anaplastic astrocytoma 29.7 PTEN OLIG2 EGFR
14 oligodendroglioma 29.7 PTEN OLIG2 EGFR
15 glioblastoma 29.6 TNC PTEN EGFR BRCA2
16 supratentorial cancer 29.5 OLIG2 EGFR
17 brain cancer 29.4 PTEN OLIG2 EGFR BRCA2
18 pancreatic ductal adenocarcinoma 29.4 PTEN EGFR BRCA2
19 endometrial adenocarcinoma 29.3 PTEN EGFR
20 lynch syndrome 29.3 PTEN EGFR BRCA2
21 sporadic breast cancer 29.2 PTEN EGFR BRCA2
22 spinal disease 29.2 PTEN OLIG2 EGFR
23 carcinosarcoma 29.0 PTEN EGFR
24 optic nerve glioma 11.5
25 brain stem glioma 11.4
26 childhood brain stem glioma 11.4
27 brain glioma 11.4
28 optic pathway glioma 11.4
29 glioma susceptibility 2 11.4
30 glioma susceptibility 9 11.4
31 glioma susceptibility 3 11.3
32 third ventricle chordoid glioma 11.3
33 chordoid glioma 11.2
34 spinal cord glioma 11.2
35 limbic encephalitis with lgi1 antibodies 11.2
36 subependymal glioma 11.2
37 astroblastoma 11.2
38 childhood optic nerve glioma 11.1
39 mixed neuronal-glial tumor 11.1
40 angiocentric glioma 11.1
41 glioma susceptibility 6 11.1
42 glioma susceptibility 8 11.1
43 glial tumor of neuroepithelial tissue with unknown origin 11.1
44 glioma susceptibility 4 11.1
45 adult brain stem glioma 11.1
46 adult brainstem mixed glioma 11.1
47 nasal glial heterotopia 11.0
48 medulloblastoma 11.0
49 anaplastic oligodendroglioma 11.0
50 rosette-forming glioneuronal tumor 11.0

Graphical network of the top 20 diseases related to Glial Tumor:



Diseases related to Glial Tumor

Symptoms & Phenotypes for Glial Tumor

GenomeRNAi Phenotypes related to Glial Tumor according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased Akt phosphorylation after EGF stimulation GR00204-A-2 8.62 PTEN PTPRB

MGI Mouse Phenotypes related to Glial Tumor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.73 BRCA2 EGFR MIF OLIG2 PTEN PTPRB
2 neoplasm MP:0002006 9.55 BRCA2 EGFR MIF OLIG2 PTEN
3 nervous system MP:0003631 9.43 BRCA2 EGFR MIF OLIG2 PTEN TNC
4 normal MP:0002873 9.02 BRCA2 EGFR MIF PTEN TNC

Drugs & Therapeutics for Glial Tumor

Drugs for Glial Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 487)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
3
Phenobarbital Approved, Investigational Phase 4 50-06-6 4763
4
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
5
Lactitol Approved, Investigational Phase 4 585-86-4 157355
6
Trametinib Approved Phase 4 871700-17-3 11707110
7
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
8
Lacosamide Approved Phase 4 860352-01-8, 175481-36-4 219078
9
Clobazam Approved, Illicit Phase 4 22316-47-8 2789
10
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
11
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
12
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
13
Topiramate Approved Phase 4 97240-79-4 5284627
14
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
15
Rufinamide Approved Phase 4 106308-44-5 129228
16 Protein Kinase Inhibitors Phase 4
17 Hypoglycemic Agents Phase 4
18 Analgesics Phase 4
19 Analgesics, Non-Narcotic Phase 4
20 Sodium Channel Blockers Phase 4
21 Diuretics, Potassium Sparing Phase 4
22 Hypnotics and Sedatives Phase 4
23 Anti-Anxiety Agents Phase 4
24 GABA Modulators Phase 4
25 Antipsychotic Agents Phase 4
26 Excitatory Amino Acid Antagonists Phase 4
27 GABA Agonists Phase 4
28
leucovorin Approved Phase 3 58-05-9 6006
29
Dextroamphetamine Approved, Illicit Phase 3 51-64-9 5826
30
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
31
Ifosfamide Approved Phase 3 3778-73-2 3690
32
Aminolevulinic acid Approved Phase 3 106-60-5 137
33
Carmustine Approved, Investigational Phase 3 154-93-8 2578
34
Dalteparin Approved Phase 3 9005-49-6
35
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
36
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
37
Trioxsalen Approved Phase 3 3902-71-4 5585
38
Somatostatin Approved, Investigational Phase 2, Phase 3 51110-01-1, 38916-34-6 53481605
39
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
40
Disulfiram Approved Phase 2, Phase 3 97-77-8 3117
41
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
42
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
43
Vinblastine Approved Phase 3 865-21-4 13342 241903
44
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
45
tannic acid Approved Phase 3 1401-55-4
46
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
47
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
48
Bevacizumab Approved, Investigational Phase 3 216974-75-3
49
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
50
Mitolactol Investigational Phase 3 10318-26-0

Interventional clinical trials:

(show top 50) (show all 1202)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
2 Seizure Treatment IN Glioma (STING): Comparing a Treatment Strategy With Levetiracetam Versus Treatment With Valproic Acid in Glioma Patients With a First Seizure Recruiting NCT03048084 Phase 4 Levetiracetam;Valproic Acid
3 A Phase IV, Prospective, Open-Label, Parallel Study Evaluating the Effect of an Adjunctive Anti-Seizure Medication Using a Glutamatergic Modulator in Patients With Focal Epilepsy and High-Grade Glioma Recruiting NCT04650204 Phase 4 Phenobarbital, Phenytoin, Carbamazepine, Valproate, Gabapentin, Pregabalin, Lamotrigine, Topiramate, Leviteracetam, Lacosamide, Zonisamide, Clobazam, Oxcarbezepine, Rufinamide;Perampanel
4 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Recruiting NCT03975829 Phase 4 dabrafenib;trametinib
5 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
6 A Study of CIK in Combination With Temozolomide With and Without Radiation in Adults With Advanced Malignant Gliomas Not yet recruiting NCT02496988 Phase 4 Temozolomide
7 A Study Evaluating Dexamfetamine Sulphate in Patients With Glioma Suffering From Severe Asthenia. A Phase III Double-blind Randomized Placebo-controlled Trial Unknown status NCT02363075 Phase 3 Dexamfetamine sulphate;placebo
8 Cognitive Rehabilitation of Glioma Patients: a Prospective, Randomized Study Unknown status NCT00256425 Phase 3
9 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
10 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
11 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
12 A Phase III Study Comparing Two Carboplatin Containing Regimens for Children and Young Adults With Previously Untreated Low Grade Glioma Unknown status NCT02455245 Phase 3 Carboplatin;Vincristine
13 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
14 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
15 Barrow 5-ALA Intraoperative Confocal Evaluation Trial Unknown status NCT01502280 Phase 3 5-Aminolevulinic acid (ALA);Placebo - ascorbic acid
16 A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma Unknown status NCT03633552 Phase 3 Temozolomide
17 Ultimate Low Grade Glioma Study Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
18 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
19 A Phase III Trial on Adjuvant Standard Temozolomide Chemotherapy With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Unknown status NCT01765088 Phase 3 Temozolomide;α-IFN
20 A Trial of Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients (PRODIGE) Completed NCT00135876 Phase 3 dalteparin
21 A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
22 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
23 PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC Completed NCT01460706 Phase 2, Phase 3 [68Ga]DOTATOC
24 DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial Completed NCT02678975 Phase 2, Phase 3 Disulfiram;Alkylating Agents
25 Clinical Study to Assess the Positive Predictive Value of NPC-07 Induced Tissue Fluorescence in Patients With Malignant Glioma (WHO Grades III/IV) Completed NCT01167322 Phase 3 NPC-07 for oral administration
26 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
27 NOA-04 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
28 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
29 A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma Completed NCT01781468 Phase 3 armodafinil 150 mg;armodafinil 250 mg
30 EFFECT OF DIBROMODULCITOL PLUS BCNU ON FREE INTERVAL AND SURVIVAL OF PATIENTS WITH SUPRATENTORIAL MALIGNANT BRAIN GLIOMAS, A PHASE III TYPE STUDY Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
31 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium
32 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
33 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
34 Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection Completed NCT00241670 Phase 3 5-aminolevulinic acid (5-ALA)
35 Primary Chemotherapy With Temozolomide Versus Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study Completed NCT00182819 Phase 3 temozolomide
36 Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma Recruiting NCT00887146 Phase 3 concomitant temozolomide (TMZ);procarbazine;adjuvant temozolomide (TMZ);CCNU;vincristine
37 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
38 Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy - A Prospective Follow-up Study Recruiting NCT03534050 Phase 2, Phase 3
39 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation Recruiting NCT04164901 Phase 3 Vorasidenib;Matching Placebo
40 IDH Mutated 1p/19q Intact Lower Grade Glioma Following Resection: Wait Or Treat? IWOT - a Phase III Study Recruiting NCT03763422 Phase 3 Temozolomide
41 Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery Recruiting NCT04316039 Phase 2, Phase 3 Temozolomide
42 A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG) Recruiting NCT03871257 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
43 A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) Recruiting NCT04166409 Phase 3 Carboplatin;Selumetinib Sulfate;Vincristine Sulfate
44 Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma Recruiting NCT01649830 Phase 3 Temozolomide
45 A Randomized Trial of Delayed Radiotherapy in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Oligodendroglial Tumors: the POLCA Trial. Recruiting NCT02444000 Phase 3 PCV chemotherapy alone;Radiotherapy+PCV chemotherapy
46 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3 β-elemene
47 A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations Recruiting NCT04576117 Phase 3 Selumetinib Sulfate;Vinblastine Sulfate
48 Interest of Fluorescein in Fluorescence-guided Resection of Gliomas: A Randomized Study Recruiting NCT03291977 Phase 3 Fluorescéine Sodique Faure
49 3.0T High-field Intraoperative MRI Guided Extent of Resection in Cerebral Glioma Surgery: a Single Center Prospective Randomized Triple-blind Controlled Clinical Trial Active, not recruiting NCT01479686 Phase 3
50 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Active, not recruiting NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat

Search NIH Clinical Center for Glial Tumor

Genetic Tests for Glial Tumor

Anatomical Context for Glial Tumor

MalaCards organs/tissues related to Glial Tumor:

40
Brain, Endothelial, T Cells, Spinal Cord, Myeloid, Bone Marrow, Pituitary

Publications for Glial Tumor

Articles related to Glial Tumor:

(show top 50) (show all 30502)
# Title Authors PMID Year
1
A novel germline mutation of PTEN associated with brain tumours of multiple lineages. 61 6
12085208 2002
2
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 6
16825431 2007
3
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 6
15689453 2005
4
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 6
14670928 2004
5
Effect of brain normalization methods on the construction of functional connectomes from resting-state functional MRI in patients with gliomas. 61
33533052 2021
6
3D bioprinted glioma microenvironment for glioma vascularization. 61
32779363 2021
7
Sevoflurane inhibits cell proliferation and migration of glioma by targeting the miR‑27b/VEGF axis. 61
33786635 2021
8
A novel derivatization strategy for profiling phosphate ester/anhydride metabolic network and application on glioma rats using HILIC-MS/MS. 61
33773740 2021
9
Rosmarinic acid inhibits cell proliferation, migration, and invasion and induces apoptosis in human glioma cells. 61
33649774 2021
10
Glioblastoma with a primitive neuroectodermal component: two cases with implications for glioblastoma cell-of-origin. 61
33406475 2021
11
miR‑124‑3p inhibits the viability and motility of glioblastoma multiforme by targeting RhoG. 61
33649803 2021
12
Abscisic Acid-Induced Autophagy Selectively via MAPK/JNK Signalling Pathway in Glioblastoma. 61
32577848 2021
13
Incidental Finding of Bilateral Thalamic Glioma on 99mTc TRODAT-1 SPECT/CT. 61
33315668 2021
14
Refractory infantile high-grade glioma containing TRK-fusion responds to larotrectinib. 61
33403813 2021
15
TSG101 Promotes the Proliferation, Migration, and Invasion of Human Glioma Cells by Regulating the AKT/GSK3β/β-Catenin and RhoC/Cofilin Pathways. 61
33411238 2021
16
Advances in the study of the role and molecular mechanism of with‑no‑lysine kinase 3 in nervous system diseases (Review). 61
33760209 2021
17
MicroRNA-383 promotes reactive oxygen species-induced autophagy via downregulating peroxiredoxin 3 in human glioma U87 cells. 61
33747176 2021
18
Upregulation of circ-ASPH contributes to glioma cell proliferation and aggressiveness by targeting the miR-599/AR/SOCS2-AS1 signaling pathway. 61
33777211 2021
19
Long non-coding RNA SUMO1P3 promotes tumour progression by regulating cell proliferation and invasion in glioma. 61
33791000 2021
20
FGL2-wired macrophages secrete CXCL7 to regulate the stem-like functionality of glioma cells. 61
33676940 2021
21
GASC1 promotes glioma progression by enhancing NOTCH1 signaling. 61
33649841 2021
22
Thalamic venous infarction from trauma mimicking a glioma. 61
33296768 2021
23
LINC01116 promotes the proliferation and invasion of glioma by regulating the microRNA‑744‑5p‑MDM2‑p53 axis. 61
33760190 2021
24
Erratum: Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells. 61
33777199 2021
25
Corilagin induces apoptosis and autophagy in NRF2‑addicted U251 glioma cell line. 61
33760110 2021
26
Modulation of untranslated region alternative polyadenylation in glioma tumorigenesis. 61
33761620 2021
27
IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87‑MG cells. 61
33760141 2021
28
Long noncoding RNA DUXAP10 promotes the stemness of glioma cells by recruiting HuR to enhance Sox12 mRNA stability. 61
33340249 2021
29
Paris saponin H inhibits the proliferation of glioma cells through the A1 and A3 adenosine receptor‑mediated pathway. 61
33537802 2021
30
Diagnostic Performance of [11C]Methionine Positron Emission Tomography in Newly Diagnosed and Untreated Glioma Based on the Revised World Health Organization 2016 Classification. 61
33444827 2021
31
Targeting Glioma Stem Cells. 61
33781508 2021
32
Mechanisms and functions of long non‑coding RNAs in glioma (Review). 61
33649805 2021
33
Forkhead box protein O3a promotes glioma cell resistance to temozolomide by regulating matrix metallopeptidase and β-catenin. 61
33692860 2021
34
Machine learning-based differentiation between multiple sclerosis and glioma WHO II°-IV° using O-(2-[18F] fluoroethyl)-L-tyrosine positron emission tomography. 61
33502678 2021
35
Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma. 61
33077924 2021
36
Hypoxia-inducible miR-196a modulates glioblastoma cell proliferation and migration through complex regulation of NRAS. 61
33469841 2021
37
Assessing fatty acid-induced lipotoxicity and its therapeutic potential in glioblastoma using stimulated Raman microscopy. 61
33795756 2021
38
CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme. 61
33581134 2021
39
Targeting post-translational histone modifying enzymes in glioblastoma. 61
33144118 2021
40
Comprehensive landscape of STEAP family functions and prognostic prediction value in glioblastoma. 61
32964440 2021
41
SH3BGRL2 functions as a crucial tumor suppressor in glioblastoma tumorigenesis. 61
33610914 2021
42
Corilagin induces human glioblastoma U251 cell apoptosis by impeding activity of (immuno)proteasome. 61
33649855 2021
43
Human TERT promoter mutations as a prognostic biomarker in glioma. 61
33547950 2021
44
High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas. 61
33444836 2021
45
Novel KRAS mutation in an unusual tectal low-grade glioma. 61
33795262 2021
46
A Histologic Low-Grade Glioma with 7 Gain, 10 Loss-A Wolf in Sheep's Clothing. 61
33714521 2021
47
Rap2B promotes the proliferation and migration of human glioma cells via activation of the ERK pathway. 61
33692846 2021
48
Genetic signature and treatment of pediatric high-grade glioma. 61
33732456 2021
49
Pharmacogenetics of ATP binding cassette transporter MDR1(1236C>T) gene polymorphism with glioma patients receiving Temozolomide-based chemoradiation therapy in Indian population. 61
33589792 2021
50
Molecular biological investigation of temozolomide and KC7F2 combination in U87MG glioma cell line. 61
33484758 2021

Variations for Glial Tumor

ClinVar genetic disease variations for Glial Tumor:

6 (show top 50) (show all 78)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 BRCA2 NM_000059.4(BRCA2):c.145G>T (p.Glu49Ter) SNV Pathogenic 51129 rs80358435 GRCh37: 13:32893291-32893291
GRCh38: 13:32319154-32319154
2 BRCA2 NM_000059.4(BRCA2):c.92G>A (p.Trp31Ter) SNV Pathogenic 52808 rs397508045 GRCh37: 13:32893238-32893238
GRCh38: 13:32319101-32319101
3 BRCA2 NM_000059.4(BRCA2):c.100G>T (p.Glu34Ter) SNV Pathogenic 51041 rs80358391 GRCh37: 13:32893246-32893246
GRCh38: 13:32319109-32319109
4 BRCA2 NM_000059.4(BRCA2):c.3109C>T (p.Gln1037Ter) SNV Pathogenic 37819 rs80358557 GRCh37: 13:32911601-32911601
GRCh38: 13:32337464-32337464
5 BRCA2 NM_000059.4(BRCA2):c.4965C>G (p.Tyr1655Ter) SNV Pathogenic 37936 rs80358721 GRCh37: 13:32913457-32913457
GRCh38: 13:32339320-32339320
6 BRCA2 NM_000059.4(BRCA2):c.6952C>T (p.Arg2318Ter) SNV Pathogenic 38076 rs80358920 GRCh37: 13:32920978-32920978
GRCh38: 13:32346841-32346841
7 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 GRCh37: 13:32954050-32954050
GRCh38: 13:32379913-32379913
8 PTEN NM_000314.7(PTEN):c.860C>G (p.Ser287Ter) SNV Pathogenic 216987 rs863224909 GRCh37: 10:89720709-89720709
GRCh38: 10:87960952-87960952
9 PTEN NM_000314.8(PTEN):c.1003C>T (p.Arg335Ter) SNV Pathogenic 7833 rs121909231 GRCh37: 10:89720852-89720852
GRCh38: 10:87961095-87961095
10 BRCA2 NM_000059.3(BRCA2):c.5791C>T (p.Gln1931Ter) SNV Pathogenic 51939 rs80358807 GRCh37: 13:32914283-32914283
GRCh38: 13:32340146-32340146
11 BRCA2 NM_000059.3(BRCA2):c.1399A>T (p.Lys467Ter) SNV Pathogenic 51118 rs80358427 GRCh37: 13:32907014-32907014
GRCh38: 13:32332877-32332877
12 PTEN NM_000314.7(PTEN):c.253+2T>A SNV Pathogenic 468676 rs1224040268 GRCh37: 10:89690848-89690848
GRCh38: 10:87931091-87931091
13 BRCA2 NM_000059.4(BRCA2):c.9117G>A (p.Pro3039=) SNV Pathogenic 38215 rs28897756 GRCh37: 13:32954050-32954050
GRCh38: 13:32379913-32379913
14 BRCA2 NM_000059.4(BRCA2):c.5857G>T (p.Glu1953Ter) SNV Pathogenic 51952 rs80358814 GRCh37: 13:32914349-32914349
GRCh38: 13:32340212-32340212
15 BRCA2 NM_000059.3(BRCA2):c.4243G>T (p.Glu1415Ter) SNV Pathogenic 37890 rs397507327 GRCh37: 13:32912735-32912735
GRCh38: 13:32338598-32338598
16 PTEN NM_000314.7(PTEN):c.517C>T (p.Arg173Cys) SNV Pathogenic 189500 rs121913293 GRCh37: 10:89711899-89711899
GRCh38: 10:87952142-87952142
17 BRCA2 NM_000059.4(BRCA2):c.6656C>G (p.Ser2219Ter) SNV Pathogenic 52149 rs80358893 GRCh37: 13:32915148-32915148
GRCh38: 13:32341011-32341011
18 BRCA2 NM_000059.4(BRCA2):c.7879A>T (p.Ile2627Phe) SNV Pathogenic 52430 rs80359014 GRCh37: 13:32936733-32936733
GRCh38: 13:32362596-32362596
19 BRCA2 NM_000059.4(BRCA2):c.7988A>T (p.Glu2663Val) SNV Pathogenic 52462 rs80359031 GRCh37: 13:32937327-32937327
GRCh38: 13:32363190-32363190
20 BRCA2 NM_000059.4(BRCA2):c.8167G>C (p.Asp2723His) SNV Pathogenic 52515 rs41293511 GRCh37: 13:32937506-32937506
GRCh38: 13:32363369-32363369
21 BRCA2 NM_000059.4(BRCA2):c.8488-1G>A SNV Pathogenic 38164 rs397507404 GRCh37: 13:32945092-32945092
GRCh38: 13:32370955-32370955
22 BRCA2 NM_000059.4(BRCA2):c.9294C>G (p.Tyr3098Ter) SNV Pathogenic 38229 rs80359200 GRCh37: 13:32968863-32968863
GRCh38: 13:32394726-32394726
23 BRCA2 NM_000059.4(BRCA2):c.9382C>T (p.Arg3128Ter) SNV Pathogenic 52826 rs80359212 GRCh37: 13:32968951-32968951
GRCh38: 13:32394814-32394814
24 BRCA2 NM_000059.4(BRCA2):c.5682C>G (p.Tyr1894Ter) SNV Pathogenic 37989 rs41293497 GRCh37: 13:32914174-32914174
GRCh38: 13:32340037-32340037
25 BRCA2 NM_000059.4(BRCA2):c.7480C>T (p.Arg2494Ter) SNV Pathogenic 38099 rs80358972 GRCh37: 13:32930609-32930609
GRCh38: 13:32356472-32356472
26 PTEN NM_000314.7(PTEN):c.701G>A (p.Arg234Gln) SNV risk factor 7840 rs121909235 GRCh37: 10:89717676-89717676
GRCh38: 10:87957919-87957919
27 PTEN NM_000314.7(PTEN):c.404T>A (p.Ile135Lys) SNV Likely pathogenic 428235 rs370795352 GRCh37: 10:89692920-89692920
GRCh38: 10:87933163-87933163
28 BRCA2 NM_000059.4(BRCA2):c.658_659del Deletion risk factor 9342 rs80359604 GRCh37: 13:32903605-32903606
GRCh38: 13:32329468-32329469
29 BRCA2 NM_000059.4(BRCA2):c.5645C>G (p.Ser1882Ter) SNV risk factor 9346 rs80358785 GRCh37: 13:32914137-32914137
GRCh38: 13:32340000-32340000
30 BRCA2 NM_000059.3(BRCA2):c.7625C>T (p.Thr2542Met) SNV Uncertain significance 96854 rs80358989 GRCh37: 13:32931886-32931886
GRCh38: 13:32357749-32357749
31 BRCA2 NM_000059.3(BRCA2):c.7051G>A (p.Ala2351Thr) SNV Uncertain significance 52256 rs80358930 GRCh37: 13:32929041-32929041
GRCh38: 13:32354904-32354904
32 PTEN NM_000314.7(PTEN):c.914G>A (p.Ser305Asn) SNV Uncertain significance 127696 rs587780007 GRCh37: 10:89720763-89720763
GRCh38: 10:87961006-87961006
33 PTEN , KLLN NM_001126049.2(KLLN):c.-736G>C SNV Uncertain significance 488964 rs1554889801 GRCh37: 10:89622980-89622980
GRCh38: 10:87863223-87863223
34 PTEN , KLLN NM_001126049.2(KLLN):c.-792C>T SNV Uncertain significance 127663 rs587779982 GRCh37: 10:89623036-89623036
GRCh38: 10:87863279-87863279
35 PTEN , KLLN NM_001126049.2(KLLN):c.-828C>T SNV Uncertain significance 187362 rs786203674 GRCh37: 10:89623072-89623072
GRCh38: 10:87863315-87863315
36 PTEN , KLLN NM_001126049.2(KLLN):c.-1039G>A SNV Uncertain significance 127682 rs587779999 GRCh37: 10:89623283-89623283
GRCh38: 10:87863526-87863526
37 PTEN NM_000314.4(PTEN):c.-868G>C SNV Uncertain significance 141949 rs587782133 GRCh37: 10:89623358-89623358
GRCh38: 10:87863601-87863601
38 PTEN NM_000314.7(PTEN):c.-834C>T SNV Uncertain significance 127676 rs587779994 GRCh37: 10:89623392-89623392
GRCh38: 10:87863635-87863635
39 PTEN NM_000314.7(PTEN):c.-821G>T SNV Uncertain significance 234510 rs587779993 GRCh37: 10:89623405-89623405
GRCh38: 10:87863648-87863648
40 PTEN NM_000314.7(PTEN):c.-764G>A SNV Uncertain significance 7844 rs587776674 GRCh37: 10:89623462-89623462
GRCh38: 10:87863705-87863705
41 BRCA2 NM_000059.3(BRCA2):c.3808G>A (p.Val1270Ile) SNV Uncertain significance 231069 rs876658938 GRCh37: 13:32912300-32912300
GRCh38: 13:32338163-32338163
42 BRCA2 NM_000059.3(BRCA2):c.6148G>A (p.Val2050Ile) SNV Uncertain significance 52019 rs80358854 GRCh37: 13:32914640-32914640
GRCh38: 13:32340503-32340503
43 PTEN NM_000314.7(PTEN):c.-665G>A SNV Uncertain significance 189528 rs553371022 GRCh37: 10:89623561-89623561
GRCh38: 10:87863804-87863804
44 PTEN NM_000314.7(PTEN):c.862G>A (p.Glu288Lys) SNV Uncertain significance 484603 rs1554825528 GRCh37: 10:89720711-89720711
GRCh38: 10:87960954-87960954
45 BRCA2 NM_000059.3(BRCA2):c.6818G>A (p.Arg2273Lys) SNV Uncertain significance 142005 rs587782174 GRCh37: 13:32915310-32915310
GRCh38: 13:32341173-32341173
46 BRCA2 NM_000059.3(BRCA2):c.8817G>C (p.Lys2939Asn) SNV Uncertain significance 38187 rs397507414 GRCh37: 13:32953516-32953516
GRCh38: 13:32379379-32379379
47 BRCA2 NM_000059.3(BRCA2):c.1433C>A (p.Thr478Lys) SNV Uncertain significance 96764 rs431825282 GRCh37: 13:32907048-32907048
GRCh38: 13:32332911-32332911
48 BRCA2 NM_000059.3(BRCA2):c.2122T>A (p.Ser708Thr) SNV Uncertain significance 51246 rs80358488 GRCh37: 13:32910614-32910614
GRCh38: 13:32336477-32336477
49 BRCA2 NM_000059.3(BRCA2):c.2186T>C (p.Ile729Thr) SNV Uncertain significance 96780 rs431825296 GRCh37: 13:32910678-32910678
GRCh38: 13:32336541-32336541
50 BRCA2 NM_000059.4(BRCA2):c.2405A>G (p.Asn802Ser) SNV Uncertain significance 234566 rs876661089 GRCh37: 13:32910897-32910897
GRCh38: 13:32336760-32336760

Expression for Glial Tumor

Search GEO for disease gene expression data for Glial Tumor.

Pathways for Glial Tumor

Pathways related to Glial Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.93 PTEN EGFR BRCA2
2 11.62 TNC PTEN EGFR
3 11.17 PTPRB EGFR
4 11.1 PTEN EGFR
5 10.99 PTEN EGFR BRCA2

GO Terms for Glial Tumor

Biological processes related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 learning or memory GO:0007611 9.26 PTEN EGFR
2 positive regulation of phosphorylation GO:0042327 9.16 MIF EGFR
3 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.13 PTEN MIF EGFR
4 negative regulation of cell aging GO:0090344 8.62 PTEN MIF

Molecular functions related to Glial Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.02 PTEN OLIG2 MIF EGFR BRCA2

Sources for Glial Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....